Therapeutic immunization with double recombinants of vaccinia virus (VACV) co-expressing sTβRII increased rejection of established TC-1 tumors in C57BL/6 mice in comparison with single recombinant expressing SigE7LAMP. Recombinant VACV derived from vaccination strain Praha expressed either the sTβRII (ectodomain) or chimeric protein fused to immunoglobulin Fc fragment (sTβRII-Fc-Jun) under control of two different promotors together with the immunogenic tumor associated antigen HPV16 E7 oncoprotein in a form of SigE7LAMP fusion molecule. The ability of soluble receptors to bind TGF-β in vitro was proved. Immunization of mice with double recombinant viruses and virus expressing SigE7LAMP only led to eliciting similar response of E7 specific CD8+ T cells as detected by IFN-γ ELISPOT.
- MeSH
- experimentální nádory terapie MeSH
- imunizace MeSH
- lidský papilomavirus 16 imunologie MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- Papillomavirus E7 - proteiny imunologie MeSH
- protein-serin-threoninkinasy genetika MeSH
- receptory transformujícího růstového faktoru beta genetika MeSH
- syntetické vakcíny imunologie MeSH
- T-lymfocyty imunologie MeSH
- vakcíny proti papilomavirům imunologie MeSH
- virus vakcinie genetika MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
